CN102858343B - 用于治疗或预防激素变化症状的方法和组合物 - Google Patents

用于治疗或预防激素变化症状的方法和组合物 Download PDF

Info

Publication number
CN102858343B
CN102858343B CN201180020427.2A CN201180020427A CN102858343B CN 102858343 B CN102858343 B CN 102858343B CN 201180020427 A CN201180020427 A CN 201180020427A CN 102858343 B CN102858343 B CN 102858343B
Authority
CN
China
Prior art keywords
dextromethorphan
symptoms
hot flashes
receptors
subtype
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CN201180020427.2A
Other languages
English (en)
Chinese (zh)
Other versions
CN102858343A (zh
Inventor
小乔治·E·罗伊斯特
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Individual
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of CN102858343A publication Critical patent/CN102858343A/zh
Application granted granted Critical
Publication of CN102858343B publication Critical patent/CN102858343B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47Quinolines; Isoquinolines
    • A61K31/485Morphinan derivatives, e.g. morphine, codeine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/185Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19Carboxylic acids, e.g. valproic acid
    • A61K31/195Carboxylic acids, e.g. valproic acid having an amino group
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00Drugs for genital or sexual disorders; Contraceptives
    • A61P15/12Drugs for genital or sexual disorders; Contraceptives for climacteric disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00Drugs for disorders of the endocrine system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Emergency Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Endocrinology (AREA)
  • Diabetes (AREA)
  • Reproductive Health (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CN201180020427.2A 2010-03-02 2011-03-01 用于治疗或预防激素变化症状的方法和组合物 Active CN102858343B (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US30963810P 2010-03-02 2010-03-02
US61/309,638 2010-03-02
PCT/US2011/026650 WO2011109367A2 (en) 2010-03-02 2011-03-01 Methods and compositions for treating or preventing symptoms of hormonal variations

Publications (2)

Publication Number Publication Date
CN102858343A CN102858343A (zh) 2013-01-02
CN102858343B true CN102858343B (zh) 2015-11-25

Family

ID=44531862

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201180020427.2A Active CN102858343B (zh) 2010-03-02 2011-03-01 用于治疗或预防激素变化症状的方法和组合物

Country Status (12)

Country Link
US (1) US20110218213A1 (https=)
EP (1) EP2542241B1 (https=)
JP (1) JP5839362B2 (https=)
CN (1) CN102858343B (https=)
AU (3) AU2011223807B2 (https=)
BR (1) BR112012022052B1 (https=)
CA (1) CA2828041C (https=)
EA (1) EA027350B1 (https=)
ES (1) ES2574210T3 (https=)
IL (2) IL221706A (https=)
PL (1) PL2542241T3 (https=)
WO (1) WO2011109367A2 (https=)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9616123B1 (en) * 2012-03-05 2017-04-11 Robert L. Knobler Method and compound for treatment of menopausal symptoms
SG11201708162UA (en) * 2015-04-07 2017-11-29 Meiji Co Ltd Hot flash-suppressing agent
WO2019094757A1 (en) 2017-11-09 2019-05-16 The Trustees Of Columbia University In The City Of New York Pharmacological prophylactics against stress-induced affective disorders in females
US11622948B2 (en) 2017-11-09 2023-04-11 The Trustees Of Columbia University In The City Of New York Biomarkers for efficacy of prophylactic treatments against stress-induced affective disorders
CA3137710A1 (en) * 2019-04-22 2020-10-29 Robert L. Knobler Non-hormonal treatment of hot flashes
US20220401366A1 (en) * 2019-11-15 2022-12-22 Consegna Pharma, Inc. Long acting nmda antagonists

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20090111846A1 (en) * 2006-02-03 2009-04-30 Avanir Pharmaceuticals Pharmaceutical compositions comprising dextromethorphan and quinidine for the treatment of depression, anxiety, and neurodegenerative disorders
CN101588804A (zh) * 2006-12-13 2009-11-25 永信药品工业股份有限公司 治疗或防治激素变异症状的方法

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5321012A (en) * 1993-01-28 1994-06-14 Virginia Commonwealth University Medical College Inhibiting the development of tolerance to and/or dependence on a narcotic addictive substance
CA2115792C (en) * 1993-03-05 2005-11-01 David J. Mayer Method for the treatment of pain
EP2283821A1 (en) * 1993-11-19 2011-02-16 Alkermes, Inc. Preparation of biodegradable microparticles containing a biologically active agent
AUPN605795A0 (en) * 1995-10-19 1995-11-09 F.H. Faulding & Co. Limited Analgesic pharmaceutical composition
ES2287021T3 (es) * 1999-07-22 2007-12-16 University Of Rochester Metodo para el tratamiento de sintomas de variacines hormonales que incluyen el fogaje.
US20040002482A1 (en) * 2000-08-30 2004-01-01 Dudley Robert E. Androgen pharmaceutical composition and method for treating depression
US6569471B2 (en) * 2000-09-01 2003-05-27 Natumin Pharma Ab Method for the treatment of symptoms related to normal hormonal variations in women
US20050129783A1 (en) * 2001-04-19 2005-06-16 Mccleary Edward L. Composition and method for treatment of neurophysiological conditions and maintenance of neurophysiological health
WO2003037334A1 (en) * 2001-10-31 2003-05-08 Merck & Co., Inc. Method for treating or preventing symptoms of hormonal variation including hot flashes
JP2006500366A (ja) * 2002-08-15 2006-01-05 ワイス 温度調節機能障害の治療ための5HT2a受容体の拮抗
HUP0303313A2 (hu) * 2003-10-09 2005-07-28 Richter Gedeon Vegyészeti Gyár Rt. Transzdermális gyógyszerkészítmények
US7855195B2 (en) * 2003-12-02 2010-12-21 Pharmaneuroboost N.V. Method of treating mental disorders using D4 and 5-HT2A antagonists, inverse agonists or partial agonists
MXPA06013163A (es) * 2004-05-11 2007-02-13 Pfizer Prod Inc Combinacion de antipsicoticos atipicos y antagonistas del receptor 5-ht1b.
CA2569411A1 (en) * 2004-06-04 2005-12-22 Mood Management Sciences, Llc Methods and compositions for treating mood disorder
EP1827450A4 (en) * 2004-11-17 2009-04-22 Cypress Bioscience Inc METHOD FOR REDUCING THE SIDE EFFECTS OF TREATMENT WITH MIRTAZAPINE
JP2009500421A (ja) * 2005-07-06 2009-01-08 セプラコア インコーポレーテッド エスゾピクロン及び抗うつ薬の組み合わせ
WO2007070779A2 (en) * 2005-12-13 2007-06-21 Trinity Laboratories, Inc. A method to treat premature ejaculation in humans
HRP20130713T1 (en) * 2007-03-19 2013-09-30 Acadia Pharmaceuticals Inc. Combinations of 5-ht2a inverse agonists and antagonists with antipsychotics
EP2323688B1 (en) * 2008-07-22 2018-10-17 MenoGeniX, Inc. Compositions and methods for treating symptoms associated with menopause, hormonal variations and arthritis

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20090111846A1 (en) * 2006-02-03 2009-04-30 Avanir Pharmaceuticals Pharmaceutical compositions comprising dextromethorphan and quinidine for the treatment of depression, anxiety, and neurodegenerative disorders
CN101588804A (zh) * 2006-12-13 2009-11-25 永信药品工业股份有限公司 治疗或防治激素变异症状的方法

Also Published As

Publication number Publication date
AU2016213776A1 (en) 2016-09-01
US20110218213A1 (en) 2011-09-08
CA2828041A1 (en) 2011-09-09
BR112012022052A2 (pt) 2020-07-07
JP2013521297A (ja) 2013-06-10
JP5839362B2 (ja) 2016-01-06
AU2011223807A1 (en) 2012-10-18
CA2828041C (en) 2018-04-17
EA027350B1 (ru) 2017-07-31
AU2011223807B2 (en) 2016-05-12
PL2542241T3 (pl) 2016-12-30
AU2018205147A1 (en) 2018-08-02
WO2011109367A3 (en) 2011-12-29
EP2542241A4 (en) 2013-11-06
CN102858343A (zh) 2013-01-02
IL221706A (en) 2017-08-31
BR112012022052B1 (pt) 2021-06-29
AU2016213776B2 (en) 2018-04-12
WO2011109367A4 (en) 2012-02-23
ES2574210T3 (es) 2016-06-15
IL253853B (en) 2019-05-30
IL253853A0 (en) 2017-09-28
EA201290851A1 (ru) 2013-04-30
EP2542241A2 (en) 2013-01-09
EP2542241B1 (en) 2016-04-27
WO2011109367A2 (en) 2011-09-09

Similar Documents

Publication Publication Date Title
US8461102B2 (en) Methods and compositions for treating and preventing symptoms of hormonal variations
US8420624B2 (en) Methods for treating or preventing symptoms of hormonal variations
AU2016213776B2 (en) Methods and compositions for treating or preventing symptoms of hormonal variations
CN101896174B (zh) 用于治疗代谢综合征的珠氯米芬
US20110124617A1 (en) Combination Therapy for BreastCancer Comprising an Antiestrogenic Agent
WO2008087491A2 (en) Method for treating or preventing symptoms of hormonal variations
EA003142B1 (ru) Лекарственное средство, обладающее антидепрессивным действием, его применение и способ лечения
CN1674880A (zh) 用于治疗体温调节机能障碍的5HT2a受体的激动作用
JP5842058B2 (ja) 自閉症の治療における使用のためのクレンブテロール
US20040180879A1 (en) Novel method of treating vasomotor symptoms
WO2008037045A2 (en) Composition containing a mixture of antidepressants for treating premature ejaculation.
Stearns Management of hot flashes in breast cancer survivors and men with prostate cancer
JP2005526713A (ja) 慢性的疼痛、興奮毒性に関連した脳障害及び心臓不整脈の治療へのアンブロキソールの使用
Leong et al. Treating recurrent postmenopausal vasomotor symptoms in a patient with a positive family history for breast cancer
CN1705475A (zh) 通过具有去甲肾上腺素重摄取抑制剂活性和5-ht2a拮抗活性的化合物治疗血管舒缩症的方法

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C14 Grant of patent or utility model
GR01 Patent grant